Physician profile
Barry Roseman
NPI 1699777474
$9,889.41
in general payments reported to CMS, 2019-2025
14 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,788 · 2020: $57.22 · 2021: $1,300 · 2022: $215 · 2023: $64.50 · 2024: $290 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $900 · Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $900.00 |
| Food and Beverage | $629.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $6,334.64 | 2019 | |
| Davol INC. | $1,421.39 | 2021-2025 | Arista |
| Isono Health, INC. | $1,053.39 | 2025 | Atusa |
| Galderma Laboratories, L.P. | $238.49 | 2019 | |
| Hologic INC | $214.83 | 2022 | |
| Medtronic, INC. | $178.30 | 2024 | Plasmablade(Tm) |
| Stemline Therapeutics INC. | $117.76 | 2019 | |
| Genzyme Corporation | $96.89 | 2019 | |
| Hologic Sales and Service, LLC | $65.27 | 2023-2024 | Localizer, Aixplorer Ultimate |
| Sanofi-Aventis U.S. LLC | $57.22 | 2020 | |
| Daiichi Sankyo INC. | $49.88 | 2024 | Enhertu |
| Smith+Nephew, INC. | $22.44 | 2024 | Pico 7, Acticoat 4" X 4" |
| Merit Medical Systems INC | $20.40 | 2024 | Savi Scout |
| Abbvie INC. | $18.51 | 2023 | Alloderm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Roseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.